Kyle Myers, MD
Family Medicine · Kearney, NENPI 1992142087
Payments from drug & device makers
Across 6 payments — averaging $129.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$550
- Cepheid$150
- Medtronic$38
- Radius Health, Inc.$23
- Inspire Medical Systems, Inc.$15
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$250
What the payments were for
- Speaking & faculty fees$70090%
- Food & beverage$7710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 2 | $550 |
| Cepheid | 1 | $150 |
| Medtronic | 1 | $38 |
| Radius Health, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$550
- XPERT CT/NG$150
How this compares
$777 in reported general payments places this provider in the 55th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $95,476 |
| OzempicSemaglutide | 79 | $80,775 |
| JardianceEmpagliflozin | 66 | $80,164 |
| MounjaroTirzepatide | 43 | $42,807 |
| XareltoRivaroxaban | 40 | $42,191 |
| TrulicityDulaglutide | 21 | $32,832 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 126 | $28,176 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $21,088 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,684 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $10,890 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,159 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $6,018 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,831 |
| Atorvastatin Calcium | 585 | $5,635 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,430 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Kearney
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.